行情

STML

STML

Stemline
NASDAQ

实时行情|Nasdaq Last Sale

7.03
0.00
0.00%
盘后: 6.98 -0.05 -0.71% 16:49 01/17 EST
开盘
7.14
昨收
7.03
最高
7.39
最低
6.94
成交量
131.80万
成交额
--
52周最高
18.22
52周最低
6.01
市值
3.52亿
市盈率(TTM)
-2.9107
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

STML 新闻

  • 拜登猛烈抨击Facebook:称扎克伯格是个“大麻烦”
  • 新浪财经综合.3小时前
  • 荔枝赴美IPO:发行价11美元/股 创始人回应亏损问题
  • 界面.3小时前
  • 菲律宾塔阿尔火山持续喷发 农业损失严重
  • 央视.3小时前
  • 苹果的透明度报告 透露各国政府对客户数据安全要求
  • 新浪财经综合.4小时前

更多

所属板块

生物技术和医学研究
-0.10%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

STML 简况

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
展开

Webull提供Stemline Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。